Real-world switching and discontinuation patterns for biologic disease-modifying antirheumatic drugs in patients with active psoriatic arthritis in Japan
Modern Rheumatology · 2026
DOI: 10.1093/mr/roaf099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2026. Verfasst von Mitsumasa Kishimoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Antirheumatic Agents, Drug Substitution, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie Inc. (North Chicago, IL, USA).
Abstract (Originalsprache)
Objectives
To evaluate switching and discontinuation of biologic disease-modifying antirheumatic drugs (bDMARDs) among psoriatic arthritis (PsA) patients in Japan over 12 months.
Methods
Claims data from the Japan Medical Data Centre (1/2005–10/2023) were analysed for patients with a PsA diagnosis on or before first bDMARD claim (index date) and ≥ 6 months of eligibility pre-index. Treatment switch (claim for another bDMARD) and discontinuation (treatment gap ≥150% days’ supply of last prescription) were evaluated up to 12 months post-index. Hazard ratios for switching and discontinuation were estimated using multivariate Cox proportional hazards models adjusted for baseline characteristics.
Results
Included patients received adalimumab (n = 323), brodalumab (n = 71), certolizumab pegol (n = 162), guselkumab (n = 157), ixekizumab (n = 239), risankizumab (n = 117), secukinumab (n = 250), or ustekinumab (n = 60). At 12 months, 21.7% switched bDMARDs and 38.1% discontinued their index bDMARD. Risankizumab had the lowest switching rate (18.4%), followed by secukinumab (19.1%) and ixekizumab (19.7%). Risankizumab had the lowest discontinuation rate (23.4%), followed by ustekinumab (27.6%) and ixekizumab (29.7%). Hazard ratios of switching and/or discontinuation were significantly higher for most bDMARDs (except ixekizumab, ustekinumab) versus risankizumab (P < .05).
Conclusions
Switching and discontinuation were common within 1-year of bDMARD treatment for PsA patients in Japan. Risankizumab demonstrated the lowest rates of switching and/or discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan.
- AbbVie Inc., North Chicago, IL, United States.
- Data Analytics & Evidence Generation, Medicus Economics, LLC, Milton, MA, United States.
- Division of Rheumatology, Department of Internal Medicine, Toho University, Tokyo, Japan.
Förderung
- AbbVie Inc. (North Chicago, IL, USA)
Zitieren
APA
Kishimoto, M., Soliman, A. M., Nunag, D., Lippe, R., Patel, M., Davis, M., & Kameda, H. (2026). Real-world switching and discontinuation patterns for biologic disease-modifying antirheumatic drugs in patients with active psoriatic arthritis in Japan. Modern Rheumatology. https://doi.org/10.1093/mr/roaf099
Vancouver
Kishimoto M, Soliman AM, Nunag D, Lippe R, Patel M, Davis M, et al. Real-world switching and discontinuation patterns for biologic disease-modifying antirheumatic drugs in patients with active psoriatic arthritis in Japan. Modern Rheumatology. 2026. doi:10.1093/mr/roaf099
BibTeX
@article{Kishimoto2026,
author = {Kishimoto, Mitsumasa and Soliman, Ahmed M and Nunag, Dominic and Lippe, Ralph and Patel, Manish and Davis, Matthew and Kameda, Hideto},
title = {Real-world switching and discontinuation patterns for biologic disease-modifying antirheumatic drugs in patients with active psoriatic arthritis in Japan},
journal = {Modern Rheumatology},
year = {2026},
doi = {10.1093/mr/roaf099}
}
EUVIMED